Objectives: We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide "additional benefit" compared to the status quo of many parallel independent national and subnational assessments. Methods: Leveraging three...

Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...

Objectives: We conducted a multi‑stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide "additional benefit" compared to the status quo of many parallel independent national and subnational assessments. Methods: Leveraging three...

Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...

This paper would like to give a contribution to the discussion on which policies and rules should be adopted in order to relaunch the pharmaceutical sector in Italy. Due to its intrinsic features, social value and being one of the most regulated and strategic as based on innovation, this sector...

There is a wide consensus among scholars of the pharmaceutical sector that the American pharmaceutical sector has been much more dynamic and successful than the European one from the mid-1990s onward. The aim of this paper is to reconsider the statistical limelights commonly adopted to justify...